Enanta Pharmaceuticals Inc. Stock
Enanta Pharmaceuticals Inc. shows a slight decrease today, losing -€0.100 (-0.850%) compared to yesterday.
Enanta Pharmaceuticals Inc. is currently one of the favorites of our community with 8 Buy predictions and no Sell predictions.
With a target price of 17 € there is a positive potential of 45.3% for Enanta Pharmaceuticals Inc. compared to the current price of 11.7 €.
So far the community has only identified positive things for Enanta Pharmaceuticals Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Enanta Pharmaceuticals Inc. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Enanta Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals Inc. | -0.850% | 0.000% | 12.500% | 48.101% | -13.971% | -75.212% | -72.010% |
| Biocryst Pharmaceuticals | -0.690% | 10.691% | 11.041% | -29.256% | -3.661% | -33.530% | -33.600% |
| Heron Therapeutics Inc. | 0.970% | 4.317% | -16.530% | -37.844% | -8.887% | -58.673% | -93.265% |
| Madrigal Pharmaceuticals inc. | -2.070% | -5.401% | -14.246% | 10.725% | -25.858% | 30.141% | 265.760% |
Comments
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Show more
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $17.00 price target on the stock.
Show more
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock.
Show more
Ratings data for ENTA provided by MarketBeat